• Fri. Sep 23rd, 2022

Dxcover launches an infrared platform: a revolutionary technology for faster sample analysis

ByRandall B. Phelps

Jun 20, 2022

DUBLIN–(BUSINESS WIRE)–Dxcover Limited, a clinical-stage diagnostics company developing spectroscopic liquid biopsy technology for the early detection of multiple cancers, today announced the launch of the Dxcover® Platform, a breakthrough platform that transforms transform-attenuated total reflectance infrared spectroscopy of Fourier (ATR-FTIR) to allow analysis of samples. Dr. Matthew Baker, Co-Founder and Chief Technology Officer, will present an overview of the technology at the 12e International Conference on Clinical Spectroscopy (SPEC) in Dublin, Ireland.

ATR-FTIR spectroscopy is a powerful analytical technique that does not require extensive sample preparation or the use of reagents. The traditional ATR method relies on an internal reflective element (IRE), which is often a fixed analysis point that requires mandatory cleaning steps to avoid cross-contamination.

The Dxcover infrared platform, however, is made up of new hardware elements that transform commercial FTIR instruments. Dxcover sample slides are made from microfabricated silicon wafers and replace the single IRE with four sample areas for one background measurement and three sample measurements. Additionally, the Dxcover Autosampler can automate the analysis of sample slides, by indexing the slide to the infrared beam without user intervention. In addition to batch processing efficiency, the Dxcover approach can be four times faster than standard ATR-FTIR instrumentation, which is optimized for clinical applications.

“Our team is excited to unveil the unique and innovative hardware of our platform at SPEC,” said Dr. Baker. “This milestone marks a significant step forward in transforming the use of infrared spectroscopy for a multitude of applications, including detecting cancer at an early stage, which maximizes the possibilities of combating or controlling disease progression. .”

Abstracts presented to SPEC include:

  • Clinical validation of a spectroscopic liquid biopsy for the early detection of brain cancer

  • Study of the effect of hereditary protein markers for a spectroscopic liquid biopsy platform

  • Early detection of multi-cancers with a spectroscopic liquid biopsy platform

  • Machine Learning Based Detection of Pancreatic Tumors Using Dxcover® Cancer Liquid Biopsy

  • Recurrent Neural Networks for Modeling Time-Domain Interferograms

  • Spinning Out Spectroscopy: development of liquid cancer biopsy Dxcover®

About Dxcover Limited

Dxcover is a clinical-stage liquid biopsy company that develops tests for the early detection of multiple cancers, when treatment has a better chance of impacting outcome. The company has pioneered the early detection and identification of cancer using infrared spectroscopy of circulating panome biomarkers. The company has generated compelling clinical data with high precision detection of stage I and stage II cancers. Dxcover is based in Scotland, UK and is expanding into the US.

For more information go to https://www.dxcover.com/science